The real-world assessment of durvalumab in patients with unresectable stage III NSCLC in the PACIFIC-R trial has highlighted important differences between this population and that of the original randomized […] Read more
It has been documented and accepted that lung cancer screening saves lives by detecting disease in high-risk individuals at earlier stages, making the disease more treatable and leading to improved […] Read more
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments. Read more
Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon. Read more
In the era of targeted treatments and immunotherapies, it is relatively common to address multiple questions in a single phase III clinical trial. These questions often involve using more than […] Read more
David R. Gandara, MD, past-president of the IASLC and director of Thoracic Oncology and senior advisor, UC Davis Comprehensive Cancer Center (UCDCCC), has always had a passion for mentorship, largely […] Read more
Although cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help […] Read more
The NELSON trial and the US National Lung Cancer Screening Trial (NLST) marked major advances in lung cancer by establishing that low-dose computed tomography (LDCT) screening of high-risk individuals is effective at catching the disease in early […] Read more
Curative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more